Tag: ViiV Healthcare

EC approves Cabotegravir LA by ViiV Healthcare for HIV prevention

businessnewstoday- September 19, 2023

ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC) has authorized Apretude, also known as cabotegravir ... Read More

Strides Pharma’s HIV generic drug gets tentative FDA approval

businessnewstoday- September 14, 2023

Strides Pharma Science Limited (Strides) announced that its Singapore-based stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, has received tentative approval for Dolutegravir 50mg ... Read More

Aurobindo Pharma gets tentative FDA approval for generic HIV treatment for children

businessnewstoday- August 16, 2023

Aurobindo Pharma Limited has achieved a significant milestone by securing the US Food and Drug Administration (FDA)'s tentative nod under the PEPFAR program for its ... Read More

Lupin gains tentative FDA approval for Dolutegravir Tablets generic

businessnewstoday- July 5, 2023

Indian pharmaceutical company Lupin announced that the US Food and Drug Administration (FDA) has granted tentative approval for its Abbreviated New Drug Application (ANDA) for ... Read More

ViiV Healthcare secures Cabenuva FDA approval for HIV-1 treatment

pharmanewsdaily- January 24, 2021

Cabenuva FDA approval : ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its long-acting regimen Cabenuva for the treatment ... Read More

ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options

pharmanewsdaily- July 4, 2020

Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a ... Read More

ViiV Healthcare secures Dovato EMA approval for HIV-1 treatment

pharmanewsdaily- July 14, 2019

Dovato EMA approval : The European Commission (EC) has approved ViiV Healthcare’s once-daily, single-pill, two-drug regimen Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus ... Read More

ViiV Healthcare secures Juluca FDA approval for virologically suppressed HIV-1

pharmanewsdaily- November 25, 2017

Juluca FDA approval : ViiV Healthcare’s 2-drug regimen Juluca has secured approval from the US Food and Drug Administration (FDA) for the maintenance treatment of ... Read More